Interim results from a phase 3 clinical trial of the BBV152 Bharat Biotech COVID-19 vaccine from India show that two doses offer 77.8% efficacy against symptomatic infection, according to a study today in The Lancet.Just last week the World Health Organization (WHO) approved emergency use of the vero cell–derived vaccine in adults.
It is the eighth COVID-19 vaccine to receive WHO emergency use listing.Led by Bharat researchers, the study involved 24,419 participants aged 18 to 97 years at 25 hospitals in India 2 weeks after the second dose of the vaccine from Nov 16, 2020, to May 17, 2021.
At the time, India experienced a peak of more than 400,000 new daily COVID-19 cases, including those caused by the Delta (B1617.2) variant.Participants